US Stock MarketDetailed Quotes
VYNE VYNE Therapeutics
- 2.7200
- -0.1700-5.88%
Close May 8 16:00 ET
38.35MMarket Cap-978P/E (TTM)
2.9200High2.6601Low30.74KVolume2.8600Open2.8900Pre Close84.95KTurnover0.33%Turnover RatioLossP/E (Static)14.10MShares7.725052wk High0.43P/B25.70MFloat Cap1.670052wk Low--Dividend TTM9.45MShs Float2869.9200Historical High--Div YieldTTM8.99%Amplitude1.6700Historical Low2.7630Avg Price1Lot Size
About VYNE Therapeutics Company
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.
Company Profile
SymbolVYNE
Company NameVYNE Therapeutics
Listing DateJan 25, 2018
Issue Price17.00
Founded2011
CEOMr. David Domzalski
MarketNASDAQ
Employees10
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address685 Route 202/206 North,Suite 301
CityBridgewater
ProvinceNew Jersey
CountryUnited States of America
Zip Code08807
Phone1-800-755-7936
Company Executives
- Name
- Position
- Salary
- David Domzalski
- President, Chief Executive Officer and Director
- 1.29M
- Mutya Harsch
- General Counsel, Chief Legal Officer and Secretary
- 654.41K
- Iain A. Stuart, PhD
- Chief Scientific Officer
- 653.93K
- Tyler Zeronda
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- --
- Patrick G. LePore
- Lead Independent Director
- 84.10K
- Dr. Christine Borowski, PhD
- Independent Director
- --
- Steven L. Basta
- Independent Director
- 44.10K
- Anthony D Bruno
- Independent Director
- 61.60K
- Sharon Surrey-Barbari
- Independent Director
- 76.60K
- Elisabeth A. Sandoval-Little
- Independent Director
- 69.10K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg